Bellerophon Therapeutics, Inc. Share Price Börse Stuttgart

Equities

6L7A

US0787713009

Biotechnology & Medical Research

Market Closed - Börse Stuttgart 11:31:13 13/10/2023 am IST 5-day change 1st Jan Change
0.421 EUR +20.98% Intraday chart for Bellerophon Therapeutics, Inc. +26.05% -45.08%

Financials

Sales 2021 - Sales 2022 - Capitalization 8.59M 8.03M 716M
Net income 2021 -17M -15.9M -1.42B Net income 2022 -19M -17.77M -1.58B EV / Sales 2021 -
Net cash position 2021 23.78M 22.24M 1.98B Net cash position 2022 6.72M 6.29M 560M EV / Sales 2022 -
P/E ratio 2021
-1.66 x
P/E ratio 2022
-0.43 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 84.97%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Bellerophon Therapeutics, Inc.

1 week+26.05%
1 month+7.12%
3 months-34.22%
6 months-95.67%
Current year-45.08%
More quotes
1 week
0.33
Extreme 0.334
0.42
1 month
0.33
Extreme 0.334
0.42
3 years
0.33
Extreme 0.334
11.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 -
Chief Tech/Sci/R&D Officer 51 29/15/29
Chief Tech/Sci/R&D Officer 63 -
Members of the board TitleAgeSince
Chairman 62 29/15/29
More insiders
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0554
Average target price
-
Consensus